SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

[X]      QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2001.

                                       OR

[ ]      TRANSITION  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO _____.


                         Commission File Number 0-18592

                           MERIT MEDICAL SYSTEMS, INC.
             (Exact name of Registrant as specified in its charter)


            Utah                                             87-0447695
            ----                                             ----------
(State or other jurisdiction of                      (I.R.S. Identification No.)
incorporation or organization)

                 1600 West Merit Parkway, South Jordan UT, 84095
                 -----------------------------------------------
                    (Address of Principal Executive Offices)


                                 (801) 253-1600
                                 --------------
              (Registrant's telephone number, including area code)


         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the  Securities  Exchange Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

Yes  x    No
   -----    ----

         Indicate the number of shares  outstanding of each of the  Registrant's
classes of common stock, as of the latest practicable date.



 Common Stock                                       7,883,055
 ------------                                       ---------
TITLE OR CLASS                           Number of Shares Outstanding at
                                                  May 14, 2001







                                            MERIT MEDICAL SYSTEMS, INC.

                                                INDEX TO FORM 10-Q



                                                                                        
PART I.     FINANCIAL INFORMATION                                                          PAGE
                                                                                           ----

  Item 1.   Financial Statements

            Consolidated Balance Sheets as of March 31, 2001
            and December 31, 2000..........................................................1

            Consolidated Statements of Operations for the three months
            ended March 31, 2001and 2000...................................................3

            Consolidated Statements of Cash Flows for the three months
            ended March 31, 2001 and 2000..................................................4

            Notes to Consolidated Financial Statements.....................................6

  Item 2.   Management's Discussion and Analysis of Financial Condition
            and Results of Operations......................................................7

  Item 3.   Qualitative and Quantitative Disclosures About Market Risk.....................9


PART II.    OTHER INFORMATION


  Item 6.    Exhibits and Reports on Form 8-K..............................................9


SIGNATURES................................................................................10





MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2001 AND DECEMBER 31, 2000
--------------------------------------------------------------------------------




                                                              March 31,      December 31,
ASSETS                                                           2001            2000
                                                             ------------    ------------
                                                              (Unaudited)
CURRENT ASSETS:
                                                                       
Cash and cash equivalents                                    $    469,092    $    412,384
Trade receivables - net                                        14,372,128      13,235,858
Employee and related
  party receivables                                               406,603         440,654
Irish Development Agency grant receivable                          46,617         177,477
Inventories                                                    23,123,591      25,273,428
Prepaid expenses and other assets                                 900,658         663,101
Deferred income tax assets                                      1,183,944       1,183,944
Income tax refund receivable                                      238,958         588,640
                                                             ------------    ------------
Total current assets                                           40,741,591      41,975,486
                                                             ------------    ------------

PROPERTY AND EQUIPMENT:
Land                                                            1,260,985       1,260,985
Building                                                        1,500,000       1,500,000
Manufacturing equipment                                        21,141,914      19,696,550
Automobiles                                                        91,496         131,036
Furniture and fixtures                                          9,632,975       9,576,084
Leasehold improvements                                          5,456,297       5,420,194
Construction-in-progress                                        1,564,479       2,120,671
                                                             ------------    ------------
Total                                                          40,648,146      39,705,520
Less accumulated depreciation
  and amortization                                            (18,788,557)    (17,860,490)
                                                             ------------    ------------
Property and equipment - net                                   21,859,589      21,845,030
                                                             ------------    ------------

OTHER ASSETS:
Patents & trademarks - net                                      2,584,214       2,522,384
Deposits                                                           38,859          41,273
Cost in excess of the fair value of assets of acquired-net      4,987,993       5,062,458
                                                             ------------    ------------
Total other assets                                              7,611,066       7,626,115
                                                             ------------    ------------

TOTAL ASSETS                                                 $ 70,212,246    $ 71,446,631
                                                             ============    ============



(Continued)
See Notes to Consolidated Financial Statements

                                        1



MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2001 AND DECEMBER 31, 2000
--------------------------------------------------------------------------------




                                                                          March 31,      December 31,
LIABILITIES AND STOCKHOLDERS' EQUITY                                        2001             2000
                                                                       -------------    -------------
                                                                          (Unaudited)
CURRENT LIABILITIES:
                                                                                   
Current portion of long-term debt                                          $ 872,428     $  1,091,725
Trade payables                                                             4,557,909        4,835,517
Accrued expenses                                                           5,113,941        3,471,039
Advances from employees                                                      138,206           96,778
Income taxes payable                                                         318,872           33,420
                                                                       -------------    -------------
Total current liabilities                                                 11,001,356        9,528,479

DEFERRED INCOME TAX LIABILITIES                                            2,210,088        2,177,833

LONG-TERM DEBT                                                            20,061,415       24,011,778

DEFERRED CREDITS                                                             914,012          955,839
                                                                       -------------    -------------

Total Liabilities                                                         34,186,871       36,673,929
                                                                       -------------    -------------


STOCKHOLDERS' EQUITY:
Preferred stock- 5,000,000  shares  authorized as of
   March 31, 2001 and December 31, 2000, respectively,
   no shares issued
Common  stock-  no  par  value;  20,000,000  shares  authorized;
   7,801,988  and 7,788,208 shares issued at March 31, 2001
   and December 31, 2000,  respectively                                   19,888,904       19,779,765
Accumulated other comprehensive loss                                        (667,029)        (624,138)
Retained earnings                                                         16,803,500       15,617,075
                                                                       -------------    -------------
Total stockholders' equity                                                36,025,375       34,772,702
                                                                       -------------    -------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                              $ 70,212,246     $ 71,446,631
                                                                        ============     ============


See Notes to Consolidated Financial Statements

                                       2


MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000         (Unaudited)
--------------------------------------------------------------------------------

                                         March 31,      March 31,
                                           2001           2000
                                      ------------   ------------
NET SALES                             $ 26,788,373   $ 22,080,435

COST OF SALES                           17,568,999     14,446,385
                                      ------------   ------------

GROSS PROFIT                             9,219,374      7,634,050
                                      ------------   ------------

OPERATING EXPENSES:
Selling, general and administrative      6,006,073      6,338,539
Research and development                 1,130,072      1,005,936
                                      ------------   ------------
TOTAL OPERATING EXPENSES                 7,136,145      7,344,475
                                      ------------   ------------

INCOME FROM OPERATIONS                   2,083,229        289,575

OTHER EXPENSE - NET                        436,067        517,404
                                      ------------   ------------

INCOME (LOSS) BEFORE INCOME TAXES        1,647,162       (227,829)

INCOME TAX EXPENSE (BENEFIT)               460,737        (68,347)

NET INCOME (LOSS)                     $  1,186,425   $   (159,482)
                                      ============   ============

EARNINGS (LOSS) PER COMMON SHARE -
    Basic and diluted                 $        .15   $       (.02)
                                      ============   ============

AVERAGE COMMON SHARES -
Basic                                    7,795,253      7,622,918
                                      ============   ============

Diluted                                  7,894,084      7,893,646
                                      ============   ============


See Notes to Consolidated Financial Statements

                                       3


MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 (Unaudited)
--------------------------------------------------------------------------------



                                                         March 31,      March 31,
                                                           2001           2000
                                                       -----------    -----------
CASH FLOWS FROM OPERATING ACTIVITIES:
                                                                
Net income (loss)                                      $ 1,186,425    $  (159,482)
                                                       -----------    -----------
Adjustments to reconcile net income to net
cash provided by (used in) in operating activities:
Depreciation and amortization                            1,112,130      1,081,220
Bad debt expense                                            59,417        390,780
Gain on sales and abandonment of
  property and equipment                                    (1,679)
Amortization of deferred credits                           (34,710)       (32,832)
Deferred income taxes                                       32,255         29,435
Changes in operating assets and liabilities:
         Trade receivables                              (1,195,687)    (1,035,235)
         Employee and related party receivables             34,051        (34,375)
         Irish Development Agency grant receivable         123,743          8,751
         Inventories                                     2,149,837       (880,489)
         Prepaid expenses and other assets                (237,557)      (292,230)
         Deposits                                            2,414        (59,970)
         Trade payables                                   (277,608)      (762,655)
         Accrued expenses                                1,642,902      1,086,493
         Advances from employees                            41,428         21,843
         Income taxes payable                              635,134       (276,511)
                                                       -----------    -----------

Total adjustments                                        4,087,749       (757,454)
                                                       -----------    -----------

Net cash provided by ( used in) operating activities     5,274,174       (916,936)
                                                       -----------    -----------

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
  Property and equipment                                  (743,856)    (1,152,049)
  Intangible assets                                        (99,029)      (127,701)
Proceeds from sale of property and equipment                   985
                                                       -----------    -----------

Net cash used in investing activities                     (842,885)    (1,278,765)
                                                       -----------    -----------



Continued on page 5
See Notes to Consolidated Financial Statements

                                       4


MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000    (Unaudited)
--------------------------------------------------------------------------------



                                                          March 31,      March 31,
                                                            2001           2000
                                                        -----------    -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
                                                                   
Borrowings under line of credit                                          1,700,576
Proceeds from issuance of  common stock                     109,139        950,608
Principal payments on:
  Long-term debt                                         (4,440,829)      (336,646)
                                                        -----------    -----------
Net cash provided by (used in) financing activities      (4,331,690)     2,314,538
                                                        -----------    -----------

EFFECT OF EXCHANGE RATES ON CASH                            (42,891)       (36,178)
                                                        -----------    -----------

NET INCREASE IN CASH                                         56,708         82,659

CASH AT BEGINNING OF PERIOD                                 412,384        668,711
                                                        -----------    -----------

CASH AT END OF PERIOD                                   $   469,092    $   751,370
                                                        ===========    ===========

SUPPLEMENTAL DISCLOSURES OF CASH
  FLOW INFORMATION:
  Cash paid during the period for:
  Interest (including capitalized interest of $16,771
     and $27,037, respectively)                         $    70,792    $   110,186
                                                        ===========    ===========
  Income taxes                                          $   118,360    $   202,327
                                                        ===========    ===========



SUPPLEMENTAL DISCLOSURE OF NONCASH
INVESTING AND FINANCING ACTIVITIES:

During the three  month  periods  ended  March 31,  2001 and 2000,  the  Company
entered into notes  payable  totaling  $271,169 and $509,963  respectively,  for
manufacturing equipment and furniture and fixtures.


See Notes to Consolidated Financial Statements

                                       5


MERIT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
--------------------------------------------------------------------------------


1.  Basis of  Presentation.  In the  opinion  of  management,  the  accompanying
consolidated  financial  statements contain all adjustments,  consisting only of
normal recurring  accruals,  necessary for a fair  presentation of the financial
position of the  Company as of March 31, 2001 and  December  31,  2000,  and the
results of its  operations  and cash flows for the three  months ended March 31,
2001 and 2000.  The results of  operations  for the three months ended March 31,
2001 and 2000 are not  necessarily  indicative  of the  results  for a full year
period.


2. Inventories. Inventories at March 31, 2001 and December 31, 2000 consisted of
the following:

                                                 March 31,      December 31,
                                                   2001             2000
                                               ------------     ------------
         Raw materials                         $  8,527,737     $  8,325,314
         Work-in-process                          3,792,119        3,678,807
         Finished goods                          12,845,048       15,255,622
         Less reserve for obsolete inventory     (2,041,313)      (1,986,315)
                                               ------------     ------------
         Total                                 $ 23,123,591     $ 25,273,428
                                               ============     ============


3. Income Taxes.  The Company has not fully allocated income tax expense between
current  and  deferred  for the  quarters  ended  March 31,  2001 and 2000.  The
effective  tax rate for the three  months ended March 31, 2001 and 2000 is below
the 35% federal  statutory tax rate, as the result of increased  researched  tax
credits now available and the Company's  profitable  operations in Ireland which
are taxed at a tax rate that is lower than the Company's U.S. overall  effective
rate.

4.  Reporting  Comprehensive  Income - In June 1997,  the  Financial  Accounting
Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS)
No.130, "Reporting Comprehensive Income." SFAS No. 130 establishes standards for
reporting  and display of  comprehensive  income and its  components  (revenues,
expenses,  gains  and  losses)  in  a  full  set  of  general-purpose  financial
statements.  This  statement  requires that an enterprise  (a) classify items of
other  comprehensive  income by their  nature in a financial  statement  and (b)
display the accumulated  balance of other  comprehensive  income separately from
retained  earnings and  additional  paid-in-capital  in the equity  section of a
statement of financial position.

Effective  January 1, 1998, the Company  adopted the provisions of SFAS No. 130.
Accordingly,  the Company determined that the only transaction  considered to be
an additional  component of  comprehensive  income is the  cumulative  effect of
foreign currency translation adjustments.  As of March 31, 2001 and December 31,
2000, the cumulative effect of such transactions reduced stockholders' equity by
approximately $667,029 and $624,138, respectively.  Comprehensive income for the
three months ended March 31, 2001 and 2000 is computed as follows:

                                                      Three Months Ended
                                                           March 31,
                                                     2001            2000
                                                -----------       -----------

          Net Income (loss)                     $ 1,186,425       $ (159,482)
          Foreign currency translation             ( 42,891)         (36,178)
                                                -----------      ------------
          Comprehensive income (loss)           $ 1,143,534       $ (195,660)
                                                ===========      ============


                                       6


MERIT MEDICAL SYSTEMS, INC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)( Continued)
--------------------------------------------------------------------------------


5.  Recently  Issued  Financial  Accounting  Standards - Statement  of Financial
Accounting Standards No.133,  Accounting for Derivative  Instruments and Hedging
Activities,  as amended,  requires that all derivative instruments be recognized
as either assets or liabilities at fair market value.  The Company  adopted this
statement  beginning  January 1, 2001.  The  effect on the  Company's  financial
statements of adopting this statement was not significant.


ITEM 2:

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
--------------------------------------------------------------------------------

Overview

Merit Medical Systems enjoyed its best quarter in history,  experiencing  record
revenues and earnings.  The Company's sales  increased  across almost all of its
product lines and  distribution  areas,  particularly in kits to packers and OEM
sales. The increased sales seem to come from a broad-based  increase in customer
ordering  patterns.  The Company  believes  that this level of  increase  may be
temporary.

Management is happy to report that the new,  comprehensive  software  system has
moved from being a major  challenge to an asset.  With this Oracle software as a
valuable tool and with the plan that  management  put in motion  starting in the
first  quarter  of 2000,  we have made  major  progress  in the  efficiency  and
profitability  of our Salt Lake  operations.  The result  has been a  tremendous
improvement from a situation of large,  unapplied overheads in the first quarter
of 2000, to significant  positive overhead variances for this quarter.  If sales
volumes continue to grow, and with  inventories at much more manageable  levels,
these positive variances bode well for improved margins in the future.

The Company is seeing real  opportunities  to  leverage  the sales,  general and
administration and research and development  strengths of the Company.  Merit is
also  significantly  reducing its inventory,  debt balances,  interest costs, as
well as effective  tax rates all of which are  contributing  to a much  improved
bottom line.

With the decline in inventories and its associated  increase in inventory turns,
and with a  significant  drop in long term debt,  the Company  has more  capital
available  to invest in  growth.  Whether  it be through  new  internal  product
development,  acquisitions  or distribution  agreements,  management has seen an
increase  in  interesting,   viable   technology   and/or  product   acquisition
opportunities.

Operations.  The Company's sales increased to record levels for the three months
ended March 31,  2001  compared  to the same  period in 2000.  The Company  also
experienced record earnings of $1.2 million for the three months ended March 31,
2001,  compared  to a net loss of  $159,482  for the same  period  of 2000.  The
following table sets forth certain operational data as a percentage of sales for
the three months ended March 31, 2001 and 2000:

                                               Three Months Ended
                                                     March 31,
                                              2001              2000
                                            --------          --------
Sales                                          100.0 %          100.0%
Gross Profit                                    34.4             34.6
Selling, general and administrative             22.4             28.7
Research and development                         4.2              4.6
Income From Operations                           7.8              1.3
Other Expense                                    1.6              2.3
Net Income (Loss)                                4.4              (.7)

                                       7


MERIT MEDICAL SYSTEMS, INC


MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (Continued)
--------------------------------------------------------------------------------

Sales.  Sales for the first quarter of 2001  increased by 21.4%,  or $4,707,938,
compared  to the same  period for 2000.  This  increase  is due to sales  volume
increases across most of the companies product families. The Company experienced
increased  sales of many of its custom kits (up 32%). To a lesser  degree,  this
increase  was  attributable  to growth in sales of  inflation  devices (up 16%),
stand alone products (up 22%) and catheters up (11%).

Gross Profit.  Gross profit as a percentage of sales  decreased  slightly in the
first  quarter  of 2001 to 34.4% as  compared  to 34.6% in the first  quarter of
2000.  The  Company's  margins are  improving  after the past three  quarters of
working  through  the  overhead  and  efficiency  deficits in the Salt Lake core
operations unit. Continued improvements are still possible at the Angleton plant
which continues to have excess inventory,  overhead and capacity that negatively
effect margins, but the negative variances are beginning to shrink.

Operating Expenses.  Operating expenses decreased  significantly as a percentage
of sales to 26.6% of sales in the first quarter of 2001 compared to 33.3% in the
first quarter of 2000. Selling, general and administrative costs as a percentage
of sales decreased to 22.4%, in 2001, compared to 28.7% for the first quarter of
2000.  The  decrease  as a  percentage  of sales in the  current  period was due
primarily to a 5.2% decline in expense while sales increased significantly. Part
of the  comparative  decline was due to the  recognition in the first quarter of
2000 of an unusual bad debt as a result of one of the Company's larger customers
going  insolvent.  Research and  development  expenses rose by $124,136 and were
4.2% of sales in the first  quarter  of 2001  compared  to 4.6% of sales for the
first  quarter of 2000.  This  increase  in  expense  was due  primarily  to the
increased  research & development  resources  associated with the new diagnostic
wire project in Ireland.

Income.  During the quarter ended March 31, 2001,  the Company  reported  income
from operations of $2,083,229,  and increase of 619% from income from operations
of $289,525 for the comparable  period in 2000. The increase in operating income
for the most recent quarter was attributable  primarily to increased sales while
selling,  general & administrative  expenses  declined.  Lower debt balances and
interest rates are helping decrease  interest  expense.  This combined for a net
income of $1,186,425 for the quarter ended March 31, 2001 compared to a net loss
of $159,482 for the same quarter of 2000.

Liquidity  and Capital  Resources.  At March 31,  2001,  the  Company's  working
capital was $29,740,235, which represented a current ratio of 3.7 to 1. In March
2001,  in an effort to reduce bank fees,  the  Company  decreased  an  available
secured bank line of credit to $22 million.  At March 31, 2000, the  outstanding
balance under the line of credit was $19,000,000. As of May 11, 2001 the line of
credit  balance has been  reduced to  $16,846,760,  or a reduction of over $13.5
million  in less  than nine  months.  Historically,  the  Company  has  incurred
significant  expenses in connection with product development and introduction of
new products.  Substantial  capital has also been required to finance  growth in
inventories and receivables. The Company's principal source of funding for these
and  other  expenses  has been  the  sale of  equity  and  cash  generated  from
operations,  secured  loans on equipment  and bank lines of credit.  The Company
believes that its present  sources of liquidity and capital are adequate for its
current operations.

Forward-Looking  Statements.  This Report includes "Forward-Looking  Statements"
within the meaning of Section 27A of the  Securities Act of 1933, as amended and
Section 21E of the Securities Exchange of 1934, as amended. All statements other
than statements of historical fact are "Forward-Looking  Statements" for purpose
of these  provisions,  including any projections of earnings,  revenues or other
financial  items,  any  statements of the plans and objectives of management for
future operations,  any statements concerning proposed new products or services,
any statements  regarding  future economic  conditions or  performance,  and any
statements of assumptions  underlying any of the foregoing.  All Forward-Looking
Statements  included  in this  document  are made as of the date  hereof and are
based on  information  available  to Merit as of such  date.  Merit  assumes  no
obligation   to  update  any  Forward-   Looking   Statement.   In  some  cases,
Forward-Looking  Statements can be identified by the use of terminology  such as
"may,"  "will,"  "expects,"  "plans,"  "anticipates,"  "intends," or "believes,"
"estimates,"  "potential,"  or  "continue,"  or the  negative  thereof  or other
comparable  terminology.  Although the Company  believes  that the  expectations
reflected in the  Forward-Looking  Statements  contained  herein are reasonable,
there can be no assurance that such  expectations or any of the  Forward-Looking
Statements will prove to be correct,  and actual results could differ materially
from  those  projected  or  assumed in the  Forward-Looking  Statements.  Future
financial  condition and results of operations,  as well as any  Forward-Looking
Statements are subject to inherent  risks and  uncertainties,  including  market
acceptance of the Company's products,  product  introductions, potential product
recalls, delays in obtaining regulatory approvals, cost increases,  fluctuations
in and obsolescence of inventory, price and product completion,  availability of

                                       8


MERIT MEDICAL SYSTEMS, INC

labor and materials,  development of new products and techniques that render the
Company's products  obsolete,  foreign currency  fluctuation,  changes in health
care  markets  related  to health  care  reform  initiatives  and other  factors
referred  to in  the  Company's  press  releases  and  reports  filed  with  the
Securities and Exchange Commission.  All subsequent  Forward-Looking  Statements
attributable  to the  Company  or person  acting  on its  behalf  are  expressly
qualified in their entirety by these cautionary statements.



ITEM 3:

QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

The Company  principally  hedges the following EURO currencies:  Belgian Francs,
French Francs, German Marks, Dutch Gilders, and Irish Pounds. The Company enters
into  forward  foreign  exchange  contracts to protect the Company from the risk
that the eventual net dollar cash flows resulting from transactions with foreign
customers  and  suppliers  may be  adversely  affected  by changes  in  currency
exchange rates. Such contracts are not significant.  The Company does not invest
in hedges for speculative proposes.






                           PART II - OTHER INFORMATION




ITEM 6:  Exhibits and Reports on Form 8-K

         (a)   Exhibits       Exhibit No.       Description
                              -----------       -----------

                                 1              Amendment to Loan Agreement with
                                                Zions First  National Bank dated
                                                March 14, 2001

         (b)   Reports  on Form 8-K - The  Company  filed a  report  on Form 8-K
               dated April 19, 2001 to report certain financial  information for
               the quarter  ended  March 31,  2001 for the purpose of  complying
               with Reg. F.D.

                                       9


MERIT MEDICAL SYSTEMS, INC



                                   SIGNATURES





Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


MERIT MEDICAL SYSTEMS, INC.
REGISTRANT





Date:     May 14, 2001            BY: /S/ FRED P. LAMPROPOULOS
          ------------            ----------------------------
                                  FRED P. LAMPROPOULOS
                                  PRESIDENT AND CHIEF EXECUTIVE OFFICER





Date:     May 14, 2001            BY: /S/ KENT W. STANGER
          ------------            -----------------------
                                  KENT W. STANGER
                                  SECRETARY AND CHIEF FINANCIAL OFFICER

                                       10